Atrial fibrillation (AF) is the most common arrhythmia in clinical practice and is associated with an increased risk of stroke, 1 heart failure, 2 and mortality. 3 Much of AF epidemiology has been derived from Western cohorts in North America and Europe, but data from non-Western cohorts are increasing and were published in our systematic review conducted 5 years ago. 1 This review reported great variability in the incidence and prevalence of AF in non-Western cohorts, especially from Asian countries. 4, 5 In recent years, epidemiologic studies on AF have been increasingly reported from Asia.
We therefore conducted an updated systematic review to present the current knowledge base of AF epidemiology by systematically reviewing the published literature in Asian countries in the 5 years since our earlier review. 1 We also explored AF incidence and the risk of stroke in AF among Asian countries by using meta-analysis. Third, "real-world" antithrombotic drug use for ischemic stroke (IS) prevention associated with AF was studied.
Materials and Methods
Methods for our review were reported previously, 1 and this update replicates our previous approach. Preferred Reporting Items for Systematic Reviews and Meta-analyses and the Meta-analyses of Observational Studies in Epidemiology guidelines were followed when performing this study. 6, 7 In brief, two reviewers (Y. B. and A. S.) searched PubMed for studies published from January 1, 2011, to September 19, 2016 , using "atrial fibrillation," "epidemiology," "prevalence," "incidence," "risk factors," "stroke," "thromboembolism," "transient ischemic attack," and names of countries in Asia according to definitions from the World Health Organization. We also listed the incidence and prevalence of AF categorized by the hospital-or community-based studies. 1 Furthermore, risk factors for AF, risk of IS in AF, and antithrombotic therapy used for stroke prevention in AF were explored. AF, including atrial flutter or not, was defined according to the definitions in the original articles. The same exclusion criteria were used for our search, including cohort size < 750, inclusion of diseases other than AF, and clinical trials, except for language exceptions; studies using both English and Chinese were eligible for this study. Studies using a duplicate data source would be excluded except for the one with the longest follow-up, or with the most recent, or the main publications, or during different periods, or with additional data relevant to the study.
The following baseline information was extracted from the studies including the main objectives: authors, cohort size, inclusion criteria, study design, and study period.
Statistical Analysis
STATA version 12.0 (StataCorp) and MedCalc version 16.5 (MedCalc Software) were used for statistical analyses. The formula event rate ¼ counts of events/person-years of observation was used in the meta-analysis. Mean follow-up period and number of included patients were multiplied to calculate personyears if not reported in the original articles. The third variable would be estimated in case of the other two provided variables. The 95% CIs of the event rate were calculated by using MedCalc. Outcomes were compared by using a fixed effects model or random effects model according to whether heterogeneity was found. The I 2 index was used to quantify heterogeneity across studies, 8 with values # 25%, 25% to 50%, and $ 50% representing low, moderate, and high degrees of heterogeneity, respectively. Begg's correlation test was used to assess publication bias. 9, 10 Weighted regression of AF rates from community-based studies in relation to increasing age was performed to show the AF rate trends with age. A two-sided P value < .05 was taken as statistically significant.
Results
A flow-chart for the search process is shown in Figure 1 . Of the identified articles, 58 studies were included from the initial 821 abstracts, including 23 hospital-based articles and 35 community-based articles. The included articles were categorized based on studied countries as follows: Chinese cohorts (People's Republic of China, Taiwan, and Hong Kong), 28; Japan, 13; South Korea, 5; Middle East, 5; Bahrain, 1; India, 3; Malaysia, 1; and Turkey, 2.
Incidence of AF
The summary annual incidence of AF was 5.38 (95% CI: 4.53-6.24) per 1,000 person-years through meta-analyzing 8, 190 AF and 3, 883, 205 person-years of data from Asian countries (mainly from Chinese, Japanese, and Korean subjects) (e- Fig 1, Table 1 ). No publication bias was observed according to Begg's test (P ¼ .79). The pooled AF annual incidence in community-based studies was 4.70 (95% CI, 3.84-5.56) per 1,000 person-years, after excluding two studies reporting the incidence of new-onset AF in hospitalbased studies. One study from Japan found that the annual incidence of hospital-based AF was 9.4 per 1,000 person-years. 11 The one study from South Korea found that the incidence of AF was 11.4 and 8.9 per 1,000 person-years in patients who had osteoporosis, with and without bisphosphonate treatment, separately.
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Community-based AF incidence varied between countries based on the eight studies. 
Community-based AF Prevalence
The lowest AF prevalence reported was 0.03% in India 21 and the highest reported was 3.75% in one study from China. 22 The latter study tested a stratified random cluster sampling method.
Within each country, community-based AF prevalence varied from 0.37% to 3.75% in the nine studies from China 4, 13, 15, 16, [22] [23] [24] [25] [26] and from 0.6% to 2.2% in the four studies from Japan. [27] [28] [29] [30] AF prevalence was relatively lower in India, from 0.03% to 0.5% based on three studies. 21, 31, 32 The prevalence of AF in South Korea, 33 Turkey, 34 and Malaysia 35 was 1.3%, 1.4%, and 0.75%, respectively. The prevalence of AF was similar in South Korea and Turkey (Fig 2, Table 2 ). The increasing AF rate in community-based studies with ageing is shown in e- Figure 2 .
AF prevalence was usually higher in men than in women among the majority of studies. 16, 22, 24, 25, 29, 33 Two articles from Malaysia and a Chinese urban community reported a similar prevalence of AF between men and women. 23, 35 The same article from China found a lower prevalence of AF in men than in women in a rural community. 23 This proportion of women to men remained low throughout the study period, with no trends for an increase even in recent years (e- Fig 3) . Hospital-based AF Prevalence AF prevalence in hospital-based studies was divided into two parts according to whether the report was associated with specific diseases. The general hospital-based prevalence of AF was reported in Japan (15.8%), 38 Qatar (9.2%), 39 and Bahrain (3.4%). 40 Hospital-based AF prevalence was also higher in men than in women in Japan (Hospital-based AF prevalence: 18.4% for men vs 11.7% for women; and 15.8% for men vs 8.8% for women). 41, 42 In specific diseases such as stroke (South Korea: 15.9% for men vs 22.4% for women) and COPD (China: 2.8% for men vs 5.2% for women), the prevalence of AF was lower in men than in women based on studies from South Korea 43 and China. 44 No reports were found regarding general hospital-based AF prevalence in Chinese cohorts; five studies on specific diseases (stable angina pectoris, chronic kidney disease, COPD, hypertension combined with diabetes mellitus, and IS) associated with AF prevalence were published. [44] [45] [46] [47] [48] Three studies from Middle Eastern countries reported AF prevalence associated with acute coronary syndrome (2.7%), 49 acute myocardial infarction (1.8%), 50 and acute heart failure (12%). 51 The first three common diseases associated with AF were stroke (18.6% in South Korea), 43 chronic kidney disease (14.2% in China), 47 and acute heart failure (12% in Screened online (N = 821)
Titles and abstracts excluded (n = 698)
Exclude:
Reviews and meta-analysis (n = 17) Assessing outcomes except for IS (n = 25) Evaluating AF associated with gene detection (n = 11) Evaluating IS associated with diseases other than AF (n = 12)
Remained for final analysis (n = 58) Categorized by country: China (n = 28), Japan (n = 13), South Korea (n = 5), Middle Eastern countries (n = 5), Bahrain (n = 1), India (n = 3), Malaysia (n = 1), and Turkey (n = 2).
Detailed evaluation (n = 123) The annual IS risk in patients without antithrombotic therapy was 4.9% in a community report from Taiwan. 59 Annual IS in AF without anticoagulant therapy was 13.3 per 1,000 person-years from one paper with mixed community-and hospital-based studies in Japan. 60 When meta-analysis was performed based on hospital-and community-based studies, the IS annual risk in AF was 3.0% (1.06%-4.95%; I 2 ¼ 99.8%; n ¼ 8), 29, 52, 53, [55] [56] [57] [58] 60 excluding the one paper with duplicate data in Taiwan Hospital-based IS prevalence in AF ranged 9.5% to 28.3% in studies from Chinese and Korean subjects 52, 54, [61] [62] [63] ; one study included data from an ED, with an IS prevalence in AF of 18.8%. 53 No separate data on IS could be extracted from the article with a thromboembolism prevalence of 15.3% in Turkey. 64 IS prevalence in AF was 0.49% (Arab) and 0.36% (South Asian) in hospital studies from Qatar. 65 Only two studies reported community-based IS prevalence in AF from China, which ranged from 1.9% to 6.0% 16, 25 (e-Tables 4-5).
Use of Antithrombotic Therapy
The use of warfarin in community-based studies from Chinese cohorts was very low, ranging from 1.0% to 4.1%, 16,25,55 whereas those from Japan were relatively high, ranging between 49.1% and 70.0%. 57, 58 In South Korea, the rate of warfarin use remained stable, ranging from 31.96% to 37.4% between 2001 and 2014. 66 The rate of antiplatelet drug use ranged widely within China (4.8%-32.3%), 16,25,55 whereas findings were similar within Japan (29.3%-32.1%) in community-based studies. 57, 58 In Chinese cohorts, eight hospital-based studies reported on warfarin anticoagulation therapy, ranging from 9.4% to 33.3%. [52] [53] [54] 61, 62, [67] [68] [69] However, therapy persistence was only 57.9% in those undergoing oral anticoagulant (OAC) treatment during the 1-year follow-up. 53 In Turkey and Middle Eastern countries, the percentage of patients undergoing warfarin treatment was < 50% in a hospital-based study. chestjournal.org
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The use of antiplatelet drugs (mainly aspirin) in hospital-based studies accounted for nearly one-half of patients with AF, ranging 40.4% to 67.6%, whether the study was in China, Turkey, or Middle Eastern countries. [52] [53] [54] 61, 62, 64, 65, 69, 70 Five hospital-based studies reported the use of non-vitamin K antagonist oral anticoagulants (NOACs) in AF, ranging from 0.6% to 6.5% 58, 61, 62, 69, 70 (e- Table 6 ).
Discussion
This updated systematic review found an incidence of AF in Asian countries of 5.38 per 1,000 person-years after meta-analyzing 10 studies from three countries. Second, the variability was apparent in the annual IS rate in patients with AF between hospital-and community-based studies (7.04% vs 1.90%). Third, the annual IS risk in patients with AF taking OACs was lower than those without anticoagulation therapy. However, the reported rate of warfarin use was < 50% in hospitals from Asian countries.
Most of the included studies assessed AF incidence and prevalence during the time period from the mid-2000s to mid-2010s. The overall and community-based incidence of new-onset AF in Asian countries was 5.38 and 4.70 per 1,000 person-years, respectively, which increased greatly compared with data extracted from the previous systematic review that included studies from 1990 to the mid-2000s. 1 We partially ascribed this higher incidence of AF to increasing age among Asian populations, 71 which is also consistent with a progressive increase in the worldwide prevalence and incidence of AF. 71 Although this theory could be confirmed in most included studies that demonstrated increased AF prevalence with age (e -Fig 2) , a large population-based prevalence study with adequate duration of follow-up is still needed in Asia. Furthermore, the community-based AF prevalence was broadly similar (0.1%-4%), but hospital-based AF prevalence was slightly higher (2.8%-14%) compared with that reported in our previous analysis.
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The community-based AF prevalence also varied widely among Asian countries (0.03%-3.75%) or even within the same country such as China (0.37%-3.75%) 4 ,13,15,16, [22] [23] [24] [25] [26] and Japan (0.6%-2.2%). [27] [28] [29] [30] The prevalence of AF in India (0.03%-0.5%) 21, 31, 32 and Malaysia (0.75%) 35 was low, partly due to the selected healthy subjects or younger outpatients in the original studies. 21, 31, 32, 35 To truly reflect the community-based AF prevalence, observational studies on populations with broader ages especially in the community-based studies from Asia. Hospital-based articles in China reported a low use of NOACs, ranging from 0.6% to 6.5%. 58, 61, 62, 69, 70 Unsurprisingly, community-based IS rates associated with AF were higher in Chinese cohorts compared with other Asian countries after meta-analysis (3.1% vs 1.9%).
Risk of stroke related to AF is usually reduced by approximately 64% with the use of OACs (eg, warfarin), and a further 19% reduction could be obtained with NOACs compared with warfarin. 77 Unfortunately, the proportion of NOAC use was low throughout the study period in Asian countries, and no trend showing an increase was seen, even in more recent years. Asian subjects also tend to have a higher risk of hemorrhagic stroke compared with non-Asian subjects, especially when taking warfarin. 78 In a US study, warfarin use with time spent in the therapeutic range $ 55% was associated with a 77% lower risk of stroke/systemic embolism compared with no antithrombotic therapy. 79 However, information on time spent in the therapeutic range and outcomes in the Asian studies we reviewed were limited.
One different result from previous studies was the inconsistent AF prevalence between men and women when studies were categorized into urban and rural settings. AF prevalence was higher in women in Chinese rural regions than in men, and similar in Chinese urban regions 23 and Malaysia. 35 The study by Wong et al 35 focused on a specific population of patients with hypertension, whereas the study by Chei et al 23 mainly
focused on elderly populations. Therefore, it would be difficult to draw any definitive conclusions due to the baseline differences among studies, which may account for the differences in AF prevalence between men and women in urban and rural settings. Other associated comorbidities, such as hyperuricemia and alcohol drinking, have been highlighted, in addition to more traditional risk factors.
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The present study did have some limitations. Unsurprisingly, interpretation of the collected data would be difficult because each study is heterogeneous: variability of incidence/prevalence of AF in Asian 40 See Figure 1 legend for expansion of abbreviation.
chestjournal.org countries may be mainly due to differences in age distribution and diagnostic strategies between developed and developing countries.
The incidence and prevalence of events (both AF and IS in AF) were generally lower in community-based studies, and underestimation may be a possibility, especially because asymptomatic AF is often neglected by the patients, and paroxysmal AF could be missed with the "one-off" ECG recordings that were commonly used in most studies. 4 Holter monitoring 11 ; no details on AF event capture provided 13 ). However, the outcomes of the included studies are broadly consistent, which reduces the risk of bias. 80 In our previous review, 1 this potential marked heterogeneity has been acknowledged and, hence, our result was not presented after a meta-analysis. Despite these limitations, our findings provide a detailed summary and comparison for AF and its associated IS epidemiology in Asia. These findings may play a role in health-care policy and decision-making in developing countries.
Conclusions
The incidence and prevalence of AF have increased in recent years, although great variability still exists in Asian countries. Variability in annual IS risk in patients with AF was evident between hospital-and communitybased studies. However, the rate of warfarin use was < 50% in hospital studies from Asian countries. 
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